Patrizia Dell’Orto
About
Patrizia Dell’Orto is a scholar working on Oncology, Cancer Research and Molecular Biology.
According to data from OpenAlex, Patrizia Dell’Orto has authored 73 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 37 papers in Cancer Research and 17 papers in Molecular Biology. Recurrent topics in Patrizia Dell’Orto's work include Breast Cancer Treatment Studies (34 papers), HER2/EGFR in Cancer Research (20 papers) and Estrogen and related hormone effects (12 papers). Patrizia Dell’Orto is often cited by papers focused on Breast Cancer Treatment Studies (34 papers), HER2/EGFR in Cancer Research (20 papers) and Estrogen and related hormone effects (12 papers). Patrizia Dell’Orto collaborates with scholars based in Italy, United States and Belgium. Patrizia Dell’Orto's co-authors include Giuseppe Viale, Guido Coggi, Aron Goldhirsch, Beat Thürlimann, Meredith M. Regan, Richard D. Gelber, Alan S. Coates, Karen N. Price, Claudio Doglioni and Patrick Neven and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.
In The Last Decade
Patrizia Dell’Orto
70 papers receiving 2.7k citations
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patrizia Dell’Orto Italy | 30 | 1.4k | 1.2k | 695 | 675 | 464 | 73 | 2.7k | ||
| Melora D. Berardo United States | 8 | 1.3k 0.9× | 962 0.8× | 811 1.2× | 509 0.8× | 422 0.9× | 10 | 2.4k | ||
| Clark Gm United States | 11 | 1.7k 1.2× | 1.5k 1.2× | 1.1k 1.6× | 629 0.9× | 418 0.9× | 14 | 3.2k | ||
| Fernanda Milanezi Portugal | 36 | 1.9k 1.3× | 1.2k 1.0× | 1.7k 2.4× | 332 0.5× | 686 1.5× | 75 | 4.0k | ||
| Jamie K. Teer United States | 32 | 1.7k 1.2× | 1.1k 0.9× | 2.1k 3.1× | 848 1.3× | 631 1.4× | 96 | 4.4k | ||
| Elisabeth Müller‐Holzner Austria | 38 | 1.5k 1.1× | 962 0.8× | 2.1k 3.1× | 539 0.8× | 308 0.7× | 99 | 4.3k | ||
| Colette Charpin France | 36 | 1.7k 1.2× | 1.3k 1.1× | 1.7k 2.4× | 526 0.8× | 358 0.8× | 135 | 3.8k | ||
| Magali Lacroix‐Triki France | 29 | 1.3k 0.9× | 1.4k 1.2× | 1.4k 2.0× | 314 0.5× | 476 1.0× | 89 | 3.1k | ||
| I D Goldberg United States | 26 | 737 0.5× | 735 0.6× | 1.5k 2.1× | 447 0.7× | 205 0.4× | 39 | 3.0k | ||
| Yoon‐La Choi South Korea | 35 | 1.6k 1.1× | 1.1k 0.9× | 1.4k 2.1× | 283 0.4× | 930 2.0× | 125 | 3.7k | ||
| F. Spyratos France | 23 | 1.0k 0.7× | 796 0.6× | 906 1.3× | 389 0.6× | 228 0.5× | 52 | 2.0k |
Countries citing papers authored by Patrizia Dell’Orto
Since
Specialization
Citations
This map shows the geographic impact of Patrizia Dell’Orto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrizia Dell’Orto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrizia Dell’Orto more than expected).
Fields of papers citing papers by Patrizia Dell’Orto
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Patrizia Dell’Orto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrizia Dell’Orto. The network helps show where Patrizia Dell’Orto may publish in the future.
Co-authorship network of co-authors of Patrizia Dell’Orto
This figure shows the co-authorship network connecting the top 25 collaborators of Patrizia Dell’Orto. A scholar is included among the top collaborators of Patrizia Dell’Orto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrizia Dell’Orto. Patrizia Dell’Orto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Luen, Stephen J., Peter Savas, Roswitha Kammler, et al.. (2025). Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials. JCO Precision Oncology. 9(9). e2400599–e2400599.
2.
Metzger, Otto, Nabihah Tayob, Giuseppe Viale, et al.. (2024). Abstract PS09-02: Event-free Survival by Residual Cancer Burden (RCB) and Intratumor HER2 Heterogeneity after Neoadjuvant T-DM1 and Pertuzumab for Early-stage HER2-positive Breast Cancer. Cancer Research. 84(9_Supplement). PS09–2.
3.
Metzger, Otto, Giuseppe Viale, Shayna Stein, et al.. (2021). Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discovery. 11(10). 2474–2487.
4.
Luen, Stephen J., Rebecca Asher, Chee Khoon Lee, et al.. (2020). Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. Annals of Oncology. 31(10). 1359–1365.
5.
Viale, Giuseppe, Femke A. de Snoo, Leen Slaets, et al.. (2017). Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial. Breast Cancer Research and Treatment. 167(1). 123–131.
6.
Viale, Giuseppe, Leen Slaets, Femke A. de Snoo, et al.. (2016). Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer. Breast Cancer Research and Treatment. 155(3). 463–469.
7.
Viale, Giuseppe, Jennifer C. Paterson, GEORGE S. CSATHY, et al.. (2016). Analysis of HER2 status in gastroesophageal tumor specimens using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay.. PubMed. 31(12). 1327–35.
8.
Viale, Giuseppe, Jennifer C. Paterson, GEORGE S. CSATHY, et al.. (2016). Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay. Pathology - Research and Practice. 212(8). 735–742.
9.
Viale, Giulia, Leen Slaets, Jan Bogaerts, et al.. (2014). High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. Annals of Oncology. 25(4). 816–823.
10.
McCullough, Ann E., Patrizia Dell’Orto, Monica M. Reinholz, et al.. (2014). Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study. Breast Cancer Research and Treatment. 143(3). 485–492.
11.
Azim, Hamdy A., Fedro A. Peccatori, Christine Desmedt, et al.. (2014). Biology of breast cancer during pregnancy using genomic profiling. Endocrine Related Cancer. 21(4). 545–554.
12.
Vingiani, Andrea, Patrick Maisonneuve, Patrizia Dell’Orto, et al.. (2013). The clinical relevance of micropapillary carcinoma of the breast: a case–control study. Histopathology. 63(2). 217–224.
13.
Viale, Giuseppe, Leen Slaets, Femke De Snoo, et al.. (2012). Comparison of molecular (BluePrint and MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial.. Journal of Clinical Oncology. 30(27_suppl). 32–32.
14.
Viale, Giuseppe, MM Regan, Patrizia Dell’Orto, et al.. (2009). Central Review of ER, PgR and HER2 in BIG 1-98 Evaluating Letrozole vs. Letrozole Followed by Tamoxifen vs. Tamoxifen Followed by Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer.. Cancer Research. 69(24_Supplement). 76–76.
15.
Giobbie‐Hurder, Anita, MM Regan, Patrizia Dell’Orto, et al.. (2008). Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from trial BIG 1-98 comparing adjuvant endocrine therapy with tamoxifen versus letrozole. Journal of Clinical Oncology. 26. 5569–5575.
16.
Torrisi, Rosalba, Nicole Rotmensz, Vincenzo Bagnardi, et al.. (2007). HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17. European Journal of Cancer. 43(16). 2339–2344.
17.
Pelosi, Giuseppe, Barbara Del Curto, Patrizia Dell’Orto, et al.. (2004). Lack of prognostic implications of HER‐2/neu abnormalities in 345 stage I nonsmall cell carcinomas (NSCLC) and 207 stage I–III neuroendocrine tumours (NET) of the lung. International Journal of Cancer. 113(1). 101–108.
18.
Manzotti, Michela, Patrizia Dell’Orto, Patrick Maisonneuve, et al.. (2000). Down-Regulation of β1C Integrin in Breast Carcinomas Correlates with High Proliferative Fraction, High Histological Grade, and Larger Size. American Journal Of Pathology. 156(1). 169–174.
19.
Coggi, Guido, et al.. (1989). Coexpression of Intermediate Filaments in Normal and Neoplastic Human Tissues: A Reappraisal. Ultrastructural Pathology. 13(5). 501–514.
20.
Viale, Giuseppe, Claudio Doglioni, P. Iuzzolino, et al.. (1988). Infantile digital fibromatosis‐like tumour (inclusion body fibromatosis) of adulthood: report of two cases with ultrastructural and immunocytochemical findings. Histopathology. 12(4). 415–424.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Melora D. Berardo Breakdown of academic impact, for papers by Clark Gm Breakdown of academic impact, for papers by Fernanda Milanezi Breakdown of academic impact, for papers by Jamie K. Teer Breakdown of academic impact, for papers by Elisabeth Müller‐Holzner Breakdown of academic impact, for papers by Colette Charpin Breakdown of academic impact, for papers by Magali Lacroix‐Triki Breakdown of academic impact, for papers by I D Goldberg Breakdown of academic impact, for papers by Yoon‐La Choi Breakdown of academic impact, for papers by F. Spyratos